Scarlet Raises $50 Million Series B for AI Medical Device Certification

Scarlet has raised $50 million in a Series B round to expand its AI-powered platform for certifying medical devices, according to a report by Pulse 2.0.

The round marks the company's second major institutional raise and directs fresh capital at one of the most persistent bottlenecks in healthcare technology: regulatory certification. Scarlet's platform applies artificial intelligence to the certification process for medical devices, a workflow that has traditionally consumed significant time and money for manufacturers bringing products to market.

What does the $50 million buy?

The Series B proceeds are earmarked for expansion of the certification platform, Pulse 2.0 reports. For a company operating in regulatory technology, scale matters on two fronts.

First, the platform itself must handle a growing volume and variety of medical devices seeking approval. AI-assisted certification tools live or die on the breadth of cases they can process accurately.

Second, expansion implies geographic and category reach. Medical device regulation differs by jurisdiction, and a certification platform that works for one market's rules must be extended to serve others if the vendor wants to grow beyond its initial footprint.

The $50 million figure places the round among the more substantial Series B raises in the healthtech compliance niche, where startups compete on the promise of compressing timelines that device makers otherwise spend on manual regulatory preparation.

Why does AI certification matter now?

Medical device makers face mounting pressure on two sides. Regulators continue to tighten scrutiny of devices, particularly those that themselves incorporate artificial intelligence. At the same time, the volume of AI-enabled medical devices reaching review has grown sharply, straining conventional certification workflows.

A platform that uses AI to streamline certification addresses both pressures at once. It offers manufacturers a faster path through documentation and compliance checks, and it gives reviewers a more consistent, machine-assisted process for evaluating submissions.

Scarlet's positioning at the intersection of AI and medical device regulation puts it in a category that has drawn sustained investor interest, as healthcare companies look for software that reduces regulatory friction rather than adding clinical features.

What comes next for Scarlet?

The stated use of the funds is expansion of the AI certification platform. For readers tracking the company, the indicators to watch are concrete: new markets added to the platform's coverage, new device categories it can certify, and any disclosure of customer growth or certification throughput following the raise.

Series B capital typically carries expectations of commercial scale rather than pure product development. If Scarlet deploys the $50 million effectively, the company will need to show that its AI-driven certification process can handle rising submission volumes while meeting the exacting standards that medical device regulators demand.

The raise signals investor confidence that regulatory automation for medical devices has graduated from a niche utility to an infrastructure business — and that Scarlet intends to build it at scale.